BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GSK2251052: Phase IIb started

In June, GlaxoSmithKline began a double-blind, U.S. Phase IIb trial to compare 750 and 1500 mg IV GSK2251052 every 12 hours vs. IV imipenem/cilastatin every 6 hours in about 200 patients....

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >